Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 7/20 | 0.34 |
| ▸ | MC5R | P33032 | 7/20 | 0.34 |
| ▸ | MC3R | P41968 | 7/20 | 0.34 |
| ▸ | MC1R | Q01726 | 7/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137349 | 0.82 | CHRM1 (0.43) | CHRM1THRBATML3MBTL1GRM5 | |
| SCHEMBL13270912 | 0.71 | MC4R (0.37) | L3MBTL1ALDH1A1MC4RMC5RMC3R | |
| SCHEMBL3140304 | 0.70 | CHRM2 (0.50) | CHRM1GRM5ALDH1A1CHRM2CHRM3 | |
| Iodide SCHEMBL3144450 | 0.70 | MC4R (0.37) | L3MBTL1MC4RMC5RMC3RMC1R | |
| SCHEMBL13677292 | 0.68 | MC4R (0.46) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL15304325 | 0.68 | GRM5 (0.49) | CHRM1GRM5ALDH1A1CHRM4CHRM5 | |
| SCHEMBL1324396 | 0.68 | EPHX1 (0.50) | MC4RMC5RMC3RMC1R | |
| SCHEMBL14111012 | 0.67 | MC4R (0.45) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL17354962 | 0.67 | CHRM1 (0.51) | CHRM1THRBATML3MBTL1GRM5 | |
| SCHEMBL10063523 | 0.67 | CHRM1 (0.51) | CHRM1THRBATML3MBTL1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610789-B1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1610789-B1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1610789-A4 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060194780-A1 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-08-31 | — | — | US | disclosed |
| EP-1610789-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087159-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194780-A1 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | CHRM1 568/4885THRB 737/4885ATM 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.